Juliette Soret

490 total citations
17 papers, 156 citations indexed

About

Juliette Soret is a scholar working on Genetics, Hematology and Rheumatology. According to data from OpenAlex, Juliette Soret has authored 17 papers receiving a total of 156 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Genetics, 13 papers in Hematology and 6 papers in Rheumatology. Recurrent topics in Juliette Soret's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (10 papers), Eosinophilic Disorders and Syndromes (6 papers) and Acute Myeloid Leukemia Research (5 papers). Juliette Soret is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (10 papers), Eosinophilic Disorders and Syndromes (6 papers) and Acute Myeloid Leukemia Research (5 papers). Juliette Soret collaborates with scholars based in France, United States and Japan. Juliette Soret's co-authors include Régis Peffault de Latour, Alexander Röth, Prasanna Kumar Nidamarthy, Peter End, Lina Benajiba, Luana Marano, Izabela Rozenberg, Serena Marotta, Flore Sicre de Fontbrune and Camilla Frieri and has published in prestigious journals such as Blood, Haematologica and JCI Insight.

In The Last Decade

Juliette Soret

14 papers receiving 156 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Juliette Soret France 6 98 77 77 57 26 17 156
Elizabeth Chalmers United Kingdom 3 81 0.8× 64 0.8× 186 2.4× 44 0.8× 31 1.2× 3 248
June Takeda Japan 6 110 1.1× 50 0.6× 120 1.6× 47 0.8× 32 1.2× 19 215
Jean‐Richard Eveillard France 6 36 0.4× 51 0.7× 79 1.0× 26 0.5× 30 1.2× 24 118
Ajay Kundra United States 6 44 0.4× 92 1.2× 82 1.1× 13 0.2× 28 1.1× 9 139
Christina Hanzis United States 8 118 1.2× 270 3.5× 92 1.2× 25 0.4× 21 0.8× 25 292
C. Starke Germany 3 30 0.3× 27 0.4× 62 0.8× 11 0.2× 16 0.6× 3 100
Mihaela Stegert Switzerland 4 72 0.7× 21 0.3× 16 0.2× 23 0.4× 10 0.4× 8 111
Elina Vervessou Greece 3 74 0.8× 234 3.0× 75 1.0× 23 0.4× 18 0.7× 4 244
Giuseppe Auteri Italy 7 22 0.2× 63 0.8× 87 1.1× 8 0.1× 52 2.0× 22 143
Eman Khatib-Massalha Israel 6 57 0.6× 25 0.3× 48 0.6× 8 0.1× 76 2.9× 11 159

Countries citing papers authored by Juliette Soret

Since Specialization
Citations

This map shows the geographic impact of Juliette Soret's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Juliette Soret with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Juliette Soret more than expected).

Fields of papers citing papers by Juliette Soret

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Juliette Soret. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Juliette Soret. The network helps show where Juliette Soret may publish in the future.

Co-authorship network of co-authors of Juliette Soret

This figure shows the co-authorship network connecting the top 25 collaborators of Juliette Soret. A scholar is included among the top collaborators of Juliette Soret based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Juliette Soret. Juliette Soret is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Ganesan, Saravanan, Fabien Guidez, Nabih Maslah, et al.. (2024). Comprehensive analysis of mesenchymal cells reveals a dysregulated TGF-β/WNT/HOXB7 axis in patients with myelofibrosis. JCI Insight. 9(23). 1 indexed citations
2.
Röth, Alexander, Satoshi Ichikawa, Yoshikazu Ito, et al.. (2023). Crovalimab treatment in patients with paroxysmal nocturnal haemoglobinuria: Long‐term results from the phase I/II COMPOSER trial. European Journal Of Haematology. 111(2). 300–310. 10 indexed citations
3.
4.
Soret, Juliette, Nabih Maslah, Marine Cazaux, et al.. (2022). Distinct Clinico-Molecular Arterial and Venous Thrombotic Scoring Systems for MPN Patients Risk Stratification. Blood. 140(Supplement 1). 830–831.
5.
Kiladjian, Jean‐Jacques, Jean‐Christophe Ianotto, Juliette Soret, et al.. (2022). Final Results of Ruxopeg, a Phase 1/2 Adaptive Randomized Trial of Ruxolitinib (Rux) and Pegylated Interferon Alpha (IFNa) 2a in Patients with Myelofibrosis (MF). Blood. 140(Supplement 1). 577–578. 14 indexed citations
6.
Ganesan, Saravanan, Fabien Guidez, Nabih Maslah, et al.. (2022). Comprehensive Analysis of Mesenchymal Cells from Myeloproliferative Neoplasm (MPN) Patients Reveals the Role of HOXB7 in Myelofibrosis Induction. Blood. 140(Supplement 1). 3852–3854.
7.
Risitano, Antonio M., Alexander Röth, Juliette Soret, et al.. (2021). Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial. The Lancet Haematology. 8(5). e344–e354. 69 indexed citations
8.
Soret, Juliette, Nicolas Gauthier, Emmanuelle Verger, et al.. (2020). SF3B1 mutations in the Driver Clone Increase the Risk of Evolution to Myelofibrosis in Patients with Myeloproliferative Neoplasms (MPN). Blood. 136(Supplement 1). 1–1. 2 indexed citations
9.
Soret, Juliette, Dominique Debray, Flore Sicre de Fontbrune, et al.. (2020). Risk factors for vascular liver diseases. Clinics and Research in Hepatology and Gastroenterology. 44(4). 410–419. 4 indexed citations
10.
Soret, Juliette, Nicolas Gauthier, Emmanuelle Verger, et al.. (2020). NFE2 Mutations Impact AML Transformation and Overall Survival in Patients with Myeloproliferative Neoplasms (MPN). Blood. 136(Supplement 1). 36–36. 2 indexed citations
11.
Röth, Alexander, Morag Griffin, Carlos M. de Castro, et al.. (2020). Effect of Pegcetacoplan on Quality of Life in Patients with Paroxysmal Nocturnal Hemoglobinuria from the Pegasus Phase 3 Trial Comparing Pegcetacoplan to Eculizumab. Blood. 136(Supplement 1). 10–12. 10 indexed citations
12.
Maslah, Nabih, Juliette Soret, Christine Dosquet, et al.. (2019). Masked polycythemia vera: analysis of a single center cohort of 2480 red cell masses. Haematologica. 105(3). e95–e97. 19 indexed citations
13.
Kelaïdi, Charikleia, Thorsten Braun, Alice Marceau‐Renaut, et al.. (2018). Outcomes and mutational analysis of patients with lower-risk non-del5q myelodysplastic syndrome treated with antithymocyte globulin with or without ciclosporine A. Leukemia Research. 71. 67–74. 3 indexed citations
14.
Kiladjian, Jean‐Jacques, et al.. (2016). Optimising the Use of Ruxolitinib in Inadequately Controlled Polycythaemia Vera. European Oncology & Haematology. 12(2). 81–81. 1 indexed citations
15.
Soret, Juliette & Jean‐Jacques Kiladjian. (2016). Place du ruxolitinib dans la stratégie thérapeutique des syndromes myéloprolifératifs. Bulletin du Cancer. 103(6). S29–S38. 2 indexed citations
16.
Glauzy, Salomé, Juliette Soret, Isabelle Fournier, et al.. (2014). Impact of acute and chronic graft-versus-host disease on human B-cell generation and replication. Blood. 124(15). 2459–2462. 18 indexed citations
17.
Kelaïdi, Charikleia, Thorsten Braun, Grégory Lazarian, et al.. (2014). Long-Term Outcome of Lower-Risk MDS Patients after Immunosuppressive Therapy (IST) with Anti-Thymocyte Globulin (ATG)+/- Cyclosporin A (CsA). Blood. 124(21). 1921–1921.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Elizabeth Chalmers Breakdown of academic impact, for papers by June Takeda Breakdown of academic impact, for papers by Jean‐Richard Eveillard Breakdown of academic impact, for papers by Ajay Kundra Breakdown of academic impact, for papers by Christina Hanzis Breakdown of academic impact, for papers by C. Starke Breakdown of academic impact, for papers by Mihaela Stegert Breakdown of academic impact, for papers by Elina Vervessou Breakdown of academic impact, for papers by Giuseppe Auteri Breakdown of academic impact, for papers by Eman Khatib-Massalha
Rankless by CCL
2026